Orchid Pharma Limited reported unaudited standalone earnings results for the second quarter and six months ended September 30, 2018. For the quarter, the reported net sales and income from operation of INR 1,424.798 million compared to INR 2,093.415 million a year ago. Total income was INR 1,487.602 million compared to INR 2,140.565 million a year ago Loss before exceptional items and tax was INR 299.121 million compared to INR 806.053 million a year ago. Net loss for the period was INR 231.251 million or INR 2.60 per basic share compared to INR 703.403 million or INR 7.91 per basic share a year ago. For the six months, the reported net sales and income from operation of INR 2,731.266 million compared to INR 3,489.778 million a year ago. Total income was INR 2,836.749 million compared to INR 3,590.700 million a year ago Loss before exceptional items and tax was INR 862.362 million compared to INR 2,112.468 million a year ago. Net loss for the period was INR 691.329 million or INR 7.77 per basic share compared to INR 1,841.295 million or INR 20.70 per basic share a year ago.